Patent ID: 8691845
Filing Date: 2014-04-08
Classification: A61P,C07C,C07D

Abstract:
1. A method of relieving, alleviating or ameliorating breast cancer, lung cancer, skin cancer, esophageal cancer, prostate cancer, glioma or leukemia in a patient comprising the administration to a patient in need thereof, a pharmacologically effective amount of a butane bridge modified tetra-O-substituted nordihydroguaiaretic acid derivative compound (BB—Sb4N), having the following general structure (Formula VI), and its pharmaceutically acceptable salts: wherein each Z is selected from the group consisting of H, —CHO, —CN, —CH -A-R; —(CH —(CH where n is an integer of 1 to 6, T a 5- to 7-member carbocyclic ring selected from the group consisting of a fully saturated ring with 1 to 3 N, O or S heteroatoms; a ring containing 1 to 3 double bonds for a 6- or 7-member ring and 1 to 2 double bonds for a 5-member ring, with 1 to 3 N, O or S heteroatoms for the 5 to 7 member ring; a ring containing a carbamate bond, a urea bond, a carbonate bond or an amide bond; and a water soluble group selected from the group consisting of an alkali metal salt of sulfonic acid; a pharmaceutically acceptable salt; a sugar and a polyhydroxy group; and A is a linear saturated hydrocarbon side chain with optional heteroatoms that is bonded at one end to the respective hydroxy residue O groups by an ether bond or a carbamate bond and at the other end to a carbon or a heteroatom in R.